Facebook
Twitter
LinkedIn
Forward2025 Wisconsin Multiple Myeloma & Lymphoma Summit
This CME-accredited activity will bring together experts in hematologic malignancies to provide a comprehensive overview of current and emerging strategies in the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia.
Designed for oncology professionals across disciplines, this program will explore practice-changing advances in both newly diagnosed and relapsed disease, with a particular focus on emerging immunotherapies, including CAR T-cell therapy and T-cell redirecting bispecific antibodies.
Expert faculty will contextualize recent clinical data and therapeutic developments, offering practical guidance on how to integrate these options into routine patient care to improve outcomes. Sessions will include in-depth analysis, case-based discussion, and multidisciplinary perspectives tailored to real-world hematology practice.
Target Audience
This activity is intended for:
- Hematologists and medical oncologists
- Oncology nurses and advanced practice providers (NPs, PAs)
- Pharmacists
- Hematology/oncology fellows
Learning Objectives
Upon successful completion of this activity, participants will be able to:
- Review induction and treatment strategies for newly diagnosed multiple myeloma, including approaches for bothtransplant-eligible and transplant-ineligible patients.
- Discuss evidence-based management of relapsed multiple myeloma, including treatment selection for patients with 1–3 prior lines of therapy.
- Evaluate the indications, efficacy, and safety profiles of novel immunotherapies, including CAR T-cell therapies and bispecific antibodies in multiple myeloma and lymphoma.
- Describe current therapeutic approaches for Waldenström Macroglobulinemia, including when and how to initiate treatment.
- Summarize evolving frontline treatment strategies for diffuse large B-cell lymphoma (DLBCL), incorporating emerging agents and combination regimens.
ORGANIZING COMMITTEE:
Course Director:
Binay Shah, MD, MHA - Binaytara
Conference Co-Chairs:
Binod Dhakal, MD - Medical College of Wisconsin
Timothy Schmidt, MD - University of Wisconsin
HOTEL INFORMATION
Coming soon
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
AGENDA COMING SOON
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.